Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD

被引:29
作者
D'Antiga, Lorenzo
Del Rizzo, Monica
Mengoli, Carlo
Cillo, Umberto
Guariso, Graziella
Zancan, Lucia
机构
[1] Univ Padua, Dept Paediat, I-35128 Padua, Italy
[2] Univ Padua, Dept Virol Microbiol & Med Biotechnol, I-35128 Padua, Italy
[3] Univ Padua, Dept Surg & Gastroenterol Sci, I-35128 Padua, Italy
关键词
D O I
10.1002/lt.20958
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Epstein-Barr virus (EBV) infection is the main cause of post-transplant lymphoproliferative disease (PTLD). Little is known on chronic carrier state and its relation with late PTLD. We aimed to study EBV infection in the long-term after paediatric liver transplantation (OLT). We conducted a retrospective review of 34 children monitored for a median of 5.8 years (range 1.5-17.7). 21 were IgG seronegative (group A) and 13 seropositive (group B) before OLT. Primary infection was the appearance of VCA-IgM or VCA-IgG or Real-Time Polymerase Chain Reaction (RT-PCR) in patients previously IgG seronegative; positive VCA-IgM or EA-IgG or RT-PCR lasting longer than 6 months was defined sustained viral detection (SVD). 18/21 patients of group A had a primary infection at a median time of 3 months after transplant (0.5-60). 14/18 of group A and 0/13 of group B had a SVD (P < 0.0001). Viral loads greater than 500 copies/10(5) mononuclear cells occur-red in 12/18 patients in group A and 0/13 patients in group B (P < 0.0001). The 3 patients who developed late PTLD (median time after OLT 47 months, range 15-121) were from group A, and presented with SVD before developing PTLD. In conclusion, EBV infection in seronegative patients at OLT is associated with greater viral loads and sustained viral detection. Late PTLD occurred only in naive patients with markers of SVD. Three to 4 monthly long-term monitoring of EBV in pre-OLT naive patients might help preventing the occurrence of late PTLD.
引用
收藏
页码:343 / 348
页数:6
相关论文
共 28 条
[1]   Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome [J].
Benkerrou, M ;
Jais, JP ;
Leblond, V ;
Durandy, A ;
Sutton, L ;
Bordigoni, P ;
Garnier, JL ;
Le Bidois, J ;
Le Deist, F ;
Blanche, S ;
Fischer, A .
BLOOD, 1998, 92 (09) :3137-3147
[2]   Case report:: Kinetics of Epstein-Barr virus load in a bone marrow transplant patient with no sign of lymphoproliferative disease [J].
Biasolo, MA ;
Calistri, A ;
Cesaro, S ;
Gentile, G ;
Mengoli, C ;
Palù, G .
JOURNAL OF MEDICAL VIROLOGY, 2003, 69 (02) :220-224
[3]  
BINGLER MA, 2005, PEDIAT TRANSPL S6, V9, pA167
[4]   Epstein-Barr virus infection. [J].
Cohen, JI .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (07) :481-492
[5]   Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-Specific T cells [J].
Comoli, P ;
Maccario, R ;
Locatelli, F ;
Valente, U ;
Basso, S ;
Garaventa, A ;
Tomà, P ;
Botti, G ;
Melioli, G ;
Baldanti, F ;
Nocera, A ;
Perfumo, F ;
Ginevri, F .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (06) :1415-1422
[6]   Late cellular rejection in paediatric liver transplantation: Aetiology and outcome [J].
D'Antiga, L ;
Dhawan, A ;
Portmann, B ;
Francavilla, R ;
Rela, M ;
Heaton, N ;
Mieli-Vergani, G .
TRANSPLANTATION, 2002, 73 (01) :80-84
[7]   VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITTS LYMPHOMA [J].
EPSTEIN, MA ;
ACHONG, BG ;
BARR, YM .
LANCET, 1964, 1 (733) :702-+
[8]   Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus [J].
Fridell, JA ;
Jain, A ;
Reyes, J ;
Biederman, R ;
Green, M ;
Sindhi, R ;
Mazariegos, GV .
TRANSPLANTATION, 2002, 74 (12) :1721-1724
[9]   Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children [J].
Green, M ;
Kaufmann, M ;
Wilson, J ;
Reyes, J .
CLINICAL INFECTIOUS DISEASES, 1997, 25 (06) :1344-1349
[10]   Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. [J].
Guthery, SL ;
Heubi, JE ;
Bucuvalas, JC ;
Gross, TG ;
Ryckman, FC ;
Alonso, MH ;
Balistreri, WF ;
Hornung, RW .
TRANSPLANTATION, 2003, 75 (07) :987-993